At 5.6% CAGR, the Europe Automated Cell Counters Market is projected to be worth US$ 2,892.10 million by 2028, says Business Market Insights           

According to Business Market Insights’ research, the Europe automated cell counters market was valued at US$ 2,085.28 million in 2022 and is expected to reach US$ 2,892.10 million by 2028, registering an annual growth rate of 5.6% from 2022 to 2028. Occurrence of infectious and chronic diseases and surge in drug discovery activities.               

The pharmaceutical & biotechnology industry generates regular experimental data that is stored on local PCs or instrument vendor servers, with vendor-dependent data. These practices result in the creation of data silos across pharma that do not adhere to data principles and prevent companies from utilizing all the information found in their raw data sets. A few automated cell counters utilize basic machine learning models that are trained on the features extracted by the software used for cell counting. Moreover, the rapid development of convolutional neural networks (CNNs) during the past few years resulted in an explosive growth of deep learning solutions for data access problems, allowing the models to learn the patterns from cell images by themselves. Big data technology helps researchers identify patterns between new diseases and genetic factors. This is likely to offer positive outcomes for future studies in biotechnology & biopharmaceutical industry, as the capacity to identify diseases has the potential to reduce patient costs and result in better quality treatment. Moreover, medical image analysis software and informatics platforms in automated cell counters have revolutionized cell-based research, which is likely to boost the demand for device-automated cell counters. Rapid scientific and technological advancements are expected to fuel the market growth in the coming years. For instance, the major advantage of a cloud-based cell counter is the use of artificial intelligence (AI) for cell detection. The AI algorithm can recognize cells based on an extensive feature set, while offline cell counters can only investigate limited features because they are restricted to the onboard processing power of the device. AI algorithms can be used to distinguish the individual cells within the cell as it aggregates more accurately. Because of the cloud-based data storage and immense computing power, the AI algorithm can be trained for storage of substantial amounts of data, including images that contain debris or cell clusters. This allows for the creation of a superior algorithm that reflects the needs of users. Therefore, use of AI, big data, and machine learning in automated cell counter is driving the growth of the market. This is expected to drive the market during the forecast period.

On the contrary, absence of skilled workforce and high cost of instrument hurdles the growth of Europe automated cell counters market. 

• Based on type, the Europe automated cell counters market is categorized into hemocytometer, flow cytometers, electrical impedance coulter counters, spectrophotometers. The spectrophotometers segment held 42.5% market share in 2022, amassing US$ 886.29 million. It is projected to garner US$ 1,247.36 million by 2028 to expand at 5.9% CAGR during 2022–2028.    
• Based on end user, the Europe automated cell counters market is categorized into hospitals, research laboratories, diagnostics centers, and others. The hospitals segment held 49.0% market share in 2022, amassing US$ 1,021.15 million. It is projected to garner US$ 1,432.13 million by 2028 to expand at 5.8% CAGR during 2022–2028.
• Based on country, the Europe automated cell counters market has been categorized into the Germany, UK, France, Italy, Spain, and Rest of Europe.  Our regional analysis states that Germany captured 26.6% market share in 2022. It was assessed at US$ 555.14 million in 2022 and is likely to hit US$ 793.88 million by 2028, exhibiting a CAGR of 6.1% during the forecast period.            

Key players dominating the Europe automated cell counters market are Eppendorf; Thermo Fisher Scientific Inc.; Countstar Inc.; Bio-Rad Laboratories, Inc.; F. Hoffman-La Roche Ltd; Chemometec A/S; ALIGNED GENETICS; Beckman Coulter, Inc. (Danaher); Nanoentek; Olympus Corporation; MERCK KGaA; Sysmex Corporation; Agilent Technologies, Inc.; Abbott; and Nexcelom Bioscience LLC. among others.

In May 2021, Bio-Rad Expands Partnership with a Major Diagnostics Company to Provide InteliQ Portfolio Quality Controls.

• In Jan 2021, Roche renews partnership with Sysmex to deliver hematology testing solutions.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com